Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

(2017) Daniel Ontaneda et al.   LANCET

Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients

(2017) Juhan Lee et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple sclerosis: experimental models and reality

(2016) Hans Lassmann et al.   ACTA NEUROPATHOLOGICA

Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy

(2016) Wai-Kay Seto et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Improving testing for hepatitis B before treatment with rituximab

(2016) Jessica K. Dyson et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity

(2016) Erin E. Longbrake et al.   JAMA Neurology

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

(2016) Mika Komori et al.   Annals of Clinical and Translational Neurology

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)

(2015) P. S. Rommer et al.   Journal of Neuroimmune Pharmacology

Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

(2015) Rui Li et al.   Science Translational Medicine

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

(2014) R. C. Dale et al.   NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Management of Multiple Sclerosis During Pregnancy and the Reproductive Years

(2014) Riley Bove et al.   OBSTETRICS AND GYNECOLOGY

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Specific peripheral B cell tolerance defects in patients with multiple sclerosis

(2013) Tuure Kinnunen et al.   JOURNAL OF CLINICAL INVESTIGATION

Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude

(2013) R. Dobson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

B cells and antibodies in multiple sclerosis pathogenesis and therapy

(2012) Markus Krumbholz et al.   Nature Reviews Neurology

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

(2011) Owain W. Howell et al.   BRAIN

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

(2011) Stephen Sawcer et al.   NATURE

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis

(2010) Roberta Magliozzi et al.   ANNALS OF NEUROLOGY

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities

(2009) H. Tremlett et al.   JOURNAL OF NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE